Recent News

• 04.15.2025 - Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
• 03.11.2025 - Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
• 03.03.2025 - TD Cowen's 45th Annual Health Care Conference
• 02.25.2025 - H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Recent Filings

• 04.10.2025 - PRE 14A Other preliminary proxy statements
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 8-K Current report
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 8-K Current report